Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News you won’t want to miss from US: https://www.marijuanamoment.net/mitch-mcconnell-tells-fda-to-clear-a-path-for-cbd-products-with-new-amendment/
Exactly. The FDA and GW Pharma are using a bogus liver study by GW Pharma that was heavily debunked by projectCBD to suggest that CBD can harm the liver and even be fatal. They are using this study as the basis of their argument to limit what can be sold to consumers without a prescription.
Hello people, we know cannabis doesn't kill people, so this Reefer Madness 2.0 scare spell being cast on the American public through the media won't last.
Another crapper with our laws is the fact that women get pregnant in Mexico and then cross the border when they're in labor. The babies are then automatic US citizens, and the women jump past the 20 year line and right into the US as residents since their children are US citizens. Living in El Paso, I actually know several of these people from Mexico that took advantage of this law. It's a broken loophole, and it needs to be fixed.
It's sad how the Democrats use the 14th Amendment to justify such a bad loophole of a law.
Not all warrants have been exercised, and the current O/S is about 78.2 million. Hypothetically, if we hit a bull run and reach the 200 MA, we could blast to $0.60 at least with all the current developments.
I would use a blender with a half head of cabbage and a quart of water. I would filter that through a wire mesh strainer and drink a half quart in morning and a half quart at night.
Since you realize that I'm not an investor here, I think that would be a safe assumption.
There are over 5000 voters in the poll.
Let me know how it goes.
Who has the better brand? --A $0.14 CBD company or CWBHF? http://allfinancetimes.com/kroger-co-nyse-kr-cbd-products-better-branding/
Drank cabbage juice for 10 days for the ulcers. Still taking regularly Pepzin GI, fiber, and Swanson ultimate probiotics daily. I also had to bland up my diet. I've tried other stuff too like Slippery Elm, Royal Jelly, DGL, and several others, but the ones I named earlier were the winners. My GI tract is 90-95% repaired.
I forgot. I also take Nat Phos 6X for the indigestion and arnica 30c for acute pain/inflammation, and I take lots of Plus CBD. --Never Ibuprofen again!
I also drink lots of Omega 3's/6's from hemp milk and take plenty of vitamin C for leaky gut repair.
The FDA approved Epidiolex because they say its benefits outweigh its risks to the liver. When I took Ibuprofen, I took it because I thought its benefits outweighed its risks to my stomach, but I was wrong about that when I was diagnosed with chronic gastritis after taking two 200 mg tabs of ibuprofen for a headache. That stuff ulcered up my stomach; I had to drink cabbage juice, probiotics, fiber, and Pepzin GI to heal myself to dodge the PPI's. So, my question is, if I can take Ibuprofen, which kills 16,000 Americans a year, why can't I take CBD? My body, my choice. BTW, GW Pharma's study on acute toxicity for the liver used doses on the equivalent of 180,000 mg per kg of body weight in ONE DOSE in a 75 kg individual. Can anyone even afford that? Then, the FDA spammed this study to the media and is using it as a basis for why we are having a conversation about the dangers of CBD, which was probably a scare tactic originating from the revolving door connection between the pharmaceutical industry and the FDA.
I mean, considering the business model, we could be successful right NOW in a highly competitive market by solely focusing on our CBD topical/supplement business since we have established such incredible brand equity --according to SPINS data. However, considering GW's revenues with Epidiolex last quarter, losing the pharmaceutical side could hurt ultra long term revenues, but wait, because I might be wrong. Here's why; our brand equity is so good right now with PlusCBD that it may be a better move at the current time to lose the pharmaceutical side and pump that money into obtaining even more brand equity to "seal the deal" on the supplement/topical side if you will. This level of success for PlusCBD was unanticipated and completely changes the ball game, and I think we should re-evaluate our plan. This is a crucial moment for the supplement side of the business. We need funds NOW to capitalize on our brand's success; we need to take on more debt and seal the deal. Plus, losing the pharma side would save us probably 10 years of trying to repay debts for clinical trials. Depending on the FDA's regulatory framework, we may be forced to keep trying on the pharma side. If it's what I anticipate--low concentration FSHE for the wellness industry and high concentration and isolated CBD for the pharma side--then redirecting all funds to the supplement/topical side of the business with our brand equity would be the best plan of action in my honest opinion.
We have to see first if they appeal or not, which would mean that the patent would still be pending since the finality of final rejections no longer applies after an appeal.
If it gets denied, CVSI will probably allocate more money to its existing CBD supplement and topical business. This would mean faster profits since not having to pay for clinical trials.
In the new CBD report I saw on stockhouse, I saw that 63% of all CBD sales will be through retail outlets by 2024. That’s big for LBUY since their business model depends on people buying from local stores. It looks like those institutional investors did some good DD before investing $4.5 million here in July.
https://stockhouse.com/news/press-releases/2019/09/12/new-report-u-s-cbd-sales-in-general-retail-forecast-to-approach-13-billion-by#xRFSMWyXC9kB4Qrg.99
Let's read it again:
I am here for the long haul, V. --The long, long, long, long haul, and until then, we'll just keep killing it with CBD supplement/topical revenues.
I do think it could be good for smokers. CBD is a relaxing substance, my nemesis.
I was a bit concerned about Mona with CVSI, but he is no longer with the company, and the valuation is considerably more attractive. However, Stanley is still with CWEB. Where else may he be committing fraud? --If he gets caught, I wouldn't want to be the one holding the bag. Once a cheater, always a cheater.
It's going to be used for smokeless tobacco addiction. --A multi-billion dollar market that's largely untapped with sub-par competitors.
But since the finality of the final rejection was removed upon appeal, then it's still pending. Look man, I'm not going to agree with you that 2+2=3. --No matter how hard you try.
Not following V. --Not following what you're saying AT ALL.
I take that Stanley is a fraud. I wouldn't want to be invested here..
If it's in appeal, then there's no final ruling yet, is there? Therefore, it's still pending. It's not a true final rejection until it fails in appeal. Think about it as if it was a court case; if I lost the case, I could appeal. It ain't over until it's over, because an appeal can lead to a reversal in decision. Since CVSI was making no revenue from the patent in question, and since the patent still has not received a final decision during appeal, there was no need to disclose any of this to investors as it isn't considered material. I can prove this too:
------------------------------------------------
Source:
THE MATERIALITY STANDARD FOR INTELLECTUAL PROPERTY DISCLOSURES by Robert S. Thomas
"Misstatements About the Status of a Patent Application Information regarding the status of a patent application can often strongly influence the value of a corporation's stock. This information is especially important when a patent application is a company's sole asset, since misstatements about the status of the patent application under these circumstances can significantly affect the value of the company's stock."
"The holding in Alna, however, seems to indicate that the status of a patent application for an invention that is of singular importance to a corporation’s viability will be material: even status about an initial rejection of the patent application."
"If a patent application is undergoing prosecution, however, it may be prudent for a corporation not to mention facts regarding that patent application at all until a final allowance or rejection on the merits has been received, so long as that patent application is not entwined with the success of the corporation."
------------------------------------------------
It seems to me that CVSI is always playing their cards right. Good luck on the lawsuit against CVSI, lol.
"Grocers Should Be Looking to Leverage $20B CBD Opportunity
By Gina Acosta - 09/11/2019
It looks like the CBD trend is not just hype, according to new research from Acosta.
In a report called “The CBD Effect: A Rapidly Emerging Consumer Trend,” marketing agency Acosta says 28% of consumers surveyed said they currently use CBD products daily or as-needed. The report projects CBD product sales to hit $20 billion by 2024.
"Health ailments without a 'one-size-fits-all treatment' are quite common and avoiding chemicals when it comes to health and self-care is important across all age groups. CBD sales and projections show consumers are turning to CBD for help, and demand is growing rapidly," said Colin Stewart, senior vice president, business intelligence at Acosta. "Consumer CBD sales are expected to reach $20 billion by 2024 — larger than the current annual sales of candy, gum and mints combined."
Since cannabidiol (CBD) was legalized by the Farm Bill in 2018, CBD products have become one of the biggest trends in retail, with many consumers turning to CBD for help with various health ailments and their general well-being. Acosta's report takes an in-depth look at the current state of the CBD industry, highlighting:
WHO IS USING CBD PRODUCTS AND WHY?
Twenty-eight percent of consumers currently use CBD products daily or as-needed.
Millennials, males and those with four-year degrees are currently the key CBD demographics. Those who reported daily or as-needed use of CBD include:
56% of Millennials
32% of Gen X
15% of Boomers
48% of men
49% of those with a bachelor's degree
Pain, mental health and general wellness are key reasons for usage, with specific health ailments varying from generation to generation. Millennials most commonly use CBD for anxiety (31%) and general wellness (30%), while Gen X and Boomers use CBD products to help with joint pain (31% and 36%, respectively) and muscle pain (both 23%).
CONSUMER PERCEPTIONS AND BARRIERS
When asked for their perspective on CBD:
55% of consumers said, "CBD oil is/might be a new miracle treatment."
35% said, "I'm not sure what to think of CBD oil."
11% said, "CBD oil is just hype."
Non-users who are open to trying CBD reported price (26%), lack of studies (18%) and distrust in claims (14%) as the biggest barriers for usage.
CBD ALREADY POPULAR WITH PET OWNERS
One in 10 pet owners reported purchasing CBD products for their pets. Of those consumers, 52% made the purchase based on a recommendation from their vet.
Top reasons for usage were pain (29%), anxiety (32%) and general wellness (29%).
The top pet CBD products include treats/chews (48%), oil (27%), capsules (14%) and topical ointment (9%).
Acosta's report was compiled using industry data and proprietary information sources including online surveys of the company's proprietary shopper community."
https://progressivegrocer.com/grocers-should-be-looking-leverage-20b-cbd-opportunity
Considering that price is considered a major barrier, Leafbuyer can help fill that void by offering the lowest prices in the area.
"Grocers Should Be Looking to Leverage $20B CBD Opportunity
By Gina Acosta - 09/11/2019
It looks like the CBD trend is not just hype, according to new research from Acosta.
In a report called “The CBD Effect: A Rapidly Emerging Consumer Trend,” marketing agency Acosta says 28% of consumers surveyed said they currently use CBD products daily or as-needed. The report projects CBD product sales to hit $20 billion by 2024.
"Health ailments without a 'one-size-fits-all treatment' are quite common and avoiding chemicals when it comes to health and self-care is important across all age groups. CBD sales and projections show consumers are turning to CBD for help, and demand is growing rapidly," said Colin Stewart, senior vice president, business intelligence at Acosta. "Consumer CBD sales are expected to reach $20 billion by 2024 — larger than the current annual sales of candy, gum and mints combined."
Since cannabidiol (CBD) was legalized by the Farm Bill in 2018, CBD products have become one of the biggest trends in retail, with many consumers turning to CBD for help with various health ailments and their general well-being. Acosta's report takes an in-depth look at the current state of the CBD industry, highlighting:
WHO IS USING CBD PRODUCTS AND WHY?
Twenty-eight percent of consumers currently use CBD products daily or as-needed.
Millennials, males and those with four-year degrees are currently the key CBD demographics. Those who reported daily or as-needed use of CBD include:
56% of Millennials
32% of Gen X
15% of Boomers
48% of men
49% of those with a bachelor's degree
Pain, mental health and general wellness are key reasons for usage, with specific health ailments varying from generation to generation. Millennials most commonly use CBD for anxiety (31%) and general wellness (30%), while Gen X and Boomers use CBD products to help with joint pain (31% and 36%, respectively) and muscle pain (both 23%).
CONSUMER PERCEPTIONS AND BARRIERS
When asked for their perspective on CBD:
55% of consumers said, "CBD oil is/might be a new miracle treatment."
35% said, "I'm not sure what to think of CBD oil."
11% said, "CBD oil is just hype."
Non-users who are open to trying CBD reported price (26%), lack of studies (18%) and distrust in claims (14%) as the biggest barriers for usage.
CBD ALREADY POPULAR WITH PET OWNERS
One in 10 pet owners reported purchasing CBD products for their pets. Of those consumers, 52% made the purchase based on a recommendation from their vet.
Top reasons for usage were pain (29%), anxiety (32%) and general wellness (29%).
The top pet CBD products include treats/chews (48%), oil (27%), capsules (14%) and topical ointment (9%).
Acosta's report was compiled using industry data and proprietary information sources including online surveys of the company's proprietary shopper community."
https://progressivegrocer.com/grocers-should-be-looking-leverage-20b-cbd-opportunity
“By definition, capitulation means to surrender or give up. In financial circles, this term is used to indicate the point in time when investors have decided to give up on trying to recapture lost gains as a result of falling stock prices. Suppose a stock you own has dropped by 10%. There are two options that can be taken: you can wait it out and hope the stock begins to appreciate, or you can realize the loss by selling the stock. If the majority of investors decides to wait it out, then stock price will likely remain relatively stable. However, if the majority of investors decides to capitulate and give up on the stock, then there will be a sharp decline in its price. When this occurrence is significant across the entire market, it is known as market capitulation.
The significance of capitulation lies in its implications. Many market professionals consider it to be a sign of a bottom in prices and consequently a good time to buy stocks. This is because basic economic factors dictate that large sell volumes will drive prices down, while large buy volumes will drive prices up. Since almost everyone who wanted (or felt forced) to sell stock has already done so, only buyers are left - and they are expected to drive the prices up.” —Investopedia
————————————————
“Leafbuyer Technologies (OTCMKTS:LBUY) operates an online platform that connects consumers with dispensaries. Shareholders of LBUY have been dealing with a harsh buzz. Having lost 90% of its value since March, the stock has basically crashed.
Since the beginning of August there has been huge volume of trading. This could be a sign of capitulation and a signal that LBUY stock is about to turn around.
Capitulation is when sellers throw in the towel. In other words, they just want to get out of the stock and put an end to their misery. They just want to sell it — and they don’t care about the price.
Ironically, this could be a bullish dynamic for the stock. This is because the sellers are about to leave the market. Due to the lack of sellers or supply that exists after this, buyers will have to pay much higher prices in order to complete their orders. This will cause the stock to rally.” —https://investorplace.com/2019/09/7-marijuana-penny-stocks-to-consider-for-those-who-can-handle-risk/
Volume appears randomly here. Just gotta stick with it. Last time I sold LBUY, it was at $2.20 pps, and I more than doubled from about $1.00. Now, it’s at $0.15; imagine if it heads to $1.00 or $2.20 again. I can’t find a single reason why it wouldn’t.
“Leafbuyer Technologies (OTCMKTS:LBUY) operates an online platform that connects consumers with dispensaries. Shareholders of LBUY have been dealing with a harsh buzz. Having lost 90% of its value since March, the stock has basically crashed.
Since the beginning of August there has been huge volume of trading. This could be a sign of capitulation and a signal that LBUY stock is about to turn around.
Capitulation is when sellers throw in the towel. In other words, they just want to get out of the stock and put an end to their misery. They just want to sell it — and they don’t care about the price.
Ironically, this could be a bullish dynamic for the stock. This is because the sellers are about to leave the market. Due to the lack of sellers or supply that exists after this, buyers will have to pay much higher prices in order to complete their orders. This will cause the stock to rally.”
https://investorplace.com/2019/09/7-marijuana-penny-stocks-to-consider-for-those-who-can-handle-risk/